Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in children

被引：0
|
作者：
Kang, Hyoung Jin
Loftus, Susan
Taylor, Arlene
DiCristina, Cara
Zwaan, Christian M.
Green, Stuart
机构：
[1] Seoul Natl Univ, Childrens Hosp, Dept Pediat Hematol & Oncol, Seoul, South Korea
[2] Merck, Harleysville, PA USA
[3] Merck Res Labs, N Wales, PA USA
[4] Merck & Co Inc, Whitehouse Stn, NJ USA
[5] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20671
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant.
    Navari, Rudolph M.
    Binder, Gary
    Bonizzoni, Erminio
    Clark-Snow, Rebecca
    Tilola, Silvia Olivari
    Roeland, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Meta-analysis of aprepitant combination regimens (ACR) for prevention of chemotherapy-induced nausea and vomiting (CINV) in adults.
    Gupta, Neha
    Hatoum, Hassan
    Al Ustwani, Omar
    Danchaivijitr, Pongwut
    Wang, Katy
    Pill, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
    Qiu, Tingting
    Men, Peng
    Sun, Tong
    Zhai, Suodi
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [34] Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
    Nakade, Susumu
    Ohno, Tomoya
    Kitagawa, Junsaku
    Hashimoto, Yoshitaka
    Katayama, Masahiro
    Awata, Hiroshi
    Kodama, Yasuo
    Miyata, Yasuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 75 - 83
  • [35] Aprepitant - A review of its use in the prevention of chemotherapy-induced nausea and vomiting
    Dando, TM
    Perry, CM
    DRUGS, 2004, 64 (07) : 777 - 794
  • [36] Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
    Susumu Nakade
    Tomoya Ohno
    Junsaku Kitagawa
    Yoshitaka Hashimoto
    Masahiro Katayama
    Hiroshi Awata
    Yasuo Kodama
    Yasuyuki Miyata
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 75 - 83
  • [37] Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT)
    Grote, T
    Hajdenberg, J
    Cartmell, A
    Ferguson, S
    Ginkel, A
    Gallagher, S
    Charu, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 794S - 794S
  • [38] Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
    Chrisp, Paul
    CORE EVIDENCE, 2007, 2 (01) : 15 - 30
  • [39] A clinical trial study on the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children with cancer
    Bahoush, Gholamreza
    Salajegheh, Pourya
    Shamshiri, Ahmadreza
    Jafari, Masoumeh
    MEDICAL SCIENCE, 2021, 25 (108) : 486 - 491
  • [40] Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
    Rashad, Noha
    Abdel-Rahman, Omar
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 947 - 954
12345